1Semba J, Watanabe A, Kito S, et al. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain[J]. Neuropharmacology,1995,34(7) : 785 - 791.
3Shapiro DA,Renoch S,Arrington E,et al.Aripiprazole,a novel atypical antipsychotie drug with a unique and robust pharmacology[J].Newropsychopharmacology,2003,28(8):1400-1411.
4Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects[J].Biol Psychiatry, 1993,33(3) :227 - 235.
5Yokoi F, Grunder G, Bizere K, et al. Dopamine Eh and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597 ) [ J ]. Neuropsychopharmacology,2002,27(3) :248 - 259.
6Hirose T, Uwahodo Y, Yameda S, et al. Efficacy and favorable side-effect profile of aripiprazole determined in rat with apomor-phine induced stereotype, catalepsy, and ptosis induction [J]. lnt J Neuropsychopharm, 2000,3 ( Suppl ) : S131 - S136.
7Petrie JL, Saha AR, McEvoy TP. Aripiprazole, a new antiosychotic;phase Ⅱ Clinical trial result[J]. Eur Neuropsychopharm,1997,7( Suppl 2) : S227 - S230.
8Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action,and risperidone vs placebo and schizoaffective disorder [ J ]. Arch Gen Psychiatry, 2003,60(7) :681 - 690.
9Kern RS,Cornblatt B,Carson WH, et al. An open-label Comparison of the neurocognitive effects of aripiprazole vs olanzapine in patients with stable psychosis [ J ]. Schizophr Res, 2001,49 (1-2) (Suppl):S234 - S237.
10Pigott TA, Carson WH,Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia:A placebo-controlled 26 week study[J]. J Clin psychiatry,2003,64(9) : 1048 - 1056.
